D. J. Slamon, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med, vol.344, issue.11, pp.783-792, 2001.

A. T. Shaw, Crizotinib in ROS1-rearranged non-small-cell lung cancer, N. Engl. J. Med, vol.371, issue.21, 1963.

A. T. Shaw, Ceritinib in ALK-rearranged non-small-cell lung cancer, N. Engl. J. Med, vol.370, issue.13, pp.1189-1197, 2014.
DOI : 10.1056/nejmoa1311107

URL : http://europepmc.org/articles/pmc4079055?pdf=render

E. A. Gehan, The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent, J. Chron. Dis, vol.13, issue.4, pp.346-353, 1961.

T. R. Fleming, One-sample multiple testing procedure for phase II clinical trials, Biometrics, pp.143-151, 1982.
DOI : 10.2307/2530297

R. Simon, Optimal two-stage designs for phase II clinical trials, Contr. Clin. Trials, vol.10, issue.1, pp.1-10, 1989.
DOI : 10.1016/0197-2456(89)90015-9

URL : http://linus.nci.nih.gov/techreport/Optimal2-StageDesigns.pdf

W. B. London and M. N. Chang, One-and two-stage designs for stratified phase II clinical trials, Stat. Med, vol.24, issue.17, pp.2597-2611, 2005.
DOI : 10.1002/sim.2139

R. Sposto and P. S. Gaynon, An adjustment for patient heterogeneity in the design of two-stage phase II trials, Stat. Med, vol.28, issue.20, pp.2566-2579, 2009.

P. F. Thall, J. K. Wathen, B. N. Bekele, R. E. Champlin, L. H. Baker et al., Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes, Stat. Med, vol.22, issue.5, pp.763-780, 2003.
DOI : 10.1002/sim.1399

J. K. Wathen, P. F. Thall, J. D. Cook, and E. H. Estey, Accounting for patient heterogeneity in phase II clinical trials, Stat. Med, vol.27, issue.15, pp.2802-2815, 2008.

L. Pusztai, K. Anderson, and K. R. Hess, Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer, Clin. Canc. Res, vol.13, issue.20, pp.6080-6086, 2007.
DOI : 10.1158/1078-0432.ccr-07-0809

URL : http://clincancerres.aacrjournals.org/content/13/20/6080.full.pdf

C. L. Jones and E. Holmgren, An adaptive Simon two-stage design for phase 2 studies of targeted therapies, Contemp. Clin. Trials, vol.28, issue.5, pp.654-661, 2007.

C. Tournoux-facon, Y. De-rycke, and P. Tubert-bitter, How a new stratified adaptive phase II design could improve targeting population, Stat. Med, vol.30, issue.13, pp.1555-1562, 2011.

D. Parashar, J. Bowden, C. Starr, L. Wernisch, and A. Mander, An optimal stratified Simon two-stage design, Pharmaceut. Stat, vol.15, issue.4, pp.330-340, 2016.
DOI : 10.1002/pst.1742

URL : http://wrap.warwick.ac.uk/78672/1/WRAP_pst1742.pdf

H. Wildiers, End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer-Alliance for Clinical Trials in Oncology-International Society of Geriatric Oncology position article, J. Clin. Oncol, vol.31, issue.29, pp.3711-3718, 2013.

L. Balducci and M. Extermann, Management of cancer in the older person: a practical approach, Oncologist, vol.5, issue.3, pp.224-237, 2000.

S. Katz, Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living, J. Am. Geriatr. Soc, vol.31, issue.12, pp.721-727, 1983.

C. A. Bellera, Screening older cancer patients: first evaluation of the G-8 geriatric screening tool, Ann. Oncol. (p, p.587, 2012.